����ӰԺ

Transaction Expected to Close Towards the End of Calendar Year 2024

SOMERSET, N.J. and COPENHAGEN, Denmark – December 6, 2024 – ����ӰԺ. (“����ӰԺ,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo Holdings”), a global life sciences investment firm, today announced that the European Commission (EC) has granted unconditional approval for the pending transaction under which Novo Holdings will acquire ����ӰԺ.

“We are pleased to have received European Commission approval, which is a significant milestone toward completing our pending transaction with Novo Holdings,” said Alessandro Maselli, President and Chief Executive Officer of ����ӰԺ. “I am deeply grateful for the ongoing commitment and efforts of the ����ӰԺ team. There is tremendous positive momentum underway at ����ӰԺ, and I believe that our future is even brighter as a private company with the support of Novo Holdings.”

“With the European Commission’s approval, we are one step closer to delivering the benefits of this transaction,” said Jonathan Levy, Senior Partner, Novo Holdings. “We look forward to supporting ����ӰԺ in its next chapter as it continues to create value for stakeholders, ultimately delivering better outcomes for the Company’s customers and the patients they serve.”

The transaction is expected to close towards the end of calendar year 2024, subject to the satisfaction of other customary closing conditions, including receipt of all requisite regulatory clearances.

For additional information associated with the transaction, please visit .

Advisors

Citi and J.P. Morgan served as financial advisors to ����ӰԺ. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to ����ӰԺ and Jones Day served as legal advisor to the ����ӰԺ Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP served as legal advisors to Novo Nordisk.

ABOUT CATALENT

����ӰԺ. (NYSE: CTLT), is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients around the world. With broad and deep scale and expertise in development sciences, delivery technologies, and multi-modality manufacturing, ����ӰԺ is a preferred industry partner for personalized medicines, consumer health brand extensions, and blockbuster drugs. ����ӰԺ helps accelerate over 1,500 partner development programs and launch over 150 new products every year. Its flexible manufacturing platforms at over 50 global sites supply nearly 70 billion doses of nearly 8,000 products annually. ����ӰԺ’s expert workforce of approximately 17,000 includes more than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the company generated approximately $4.4 billion in revenue in its 2024 fiscal year. For more information, visit www.catalent.com.

About Novo Holdings

Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.

Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.

Forward-Looking Statements

This press release, and any related oral statements, may include both historical and forward-looking statements and guidance. All statements other than statements of historical fact, are, or may be deemed to be, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of statements that include phrases such as “believe,” “expect,” “anticipate,” “intend,” “estimate,” “plan,” “project,” “predict,” “hope,” “foresee,” “likely,” “may,” “could,” “target,” “will,” “would,” or other words or phrases with similar meanings. Similarly, statements that describe ����ӰԺ’s objectives, plans, or goals are, or may be, forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from ����ӰԺ’s expectations, projections, and guidance. Some of the factors that could cause actual results to differ materially from forward-looking statements include, but are not limited to, the pending merger of ����ӰԺ with an affiliate of Novo Holdings (the “Merger”), the completion of the Merger on anticipated terms and timing, including obtaining antitrust and other regulatory approvals and clearances, the satisfaction of other conditions to the completion of the Merger, potential litigation relating to the Merger that could be instituted by or against ����ӰԺ, Novo Holdings or their respective affiliates, directors or officers, including the effects of any outcomes related thereto, the risk that disruptions from the Merger will harm ����ӰԺ’s relationships, and certain restrictions during the pendency of the Merger that may impact ����ӰԺ’s ability to pursue attractive business opportunities or strategic transactions.

These forward-looking statements speak only as of the date of this press release or as of the date they are made, and ����ӰԺ does not undertake to and specifically disclaims any obligation to publicly release the results of any updates or revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

Contacts:

����ӰԺ
Investor Contact:
Paul Surdez
+1 (732) 537-6325
[email protected]

Media Contact:
Laura Hortas
+1(609) 240-7025
[email protected]

Novo Holdings
(Global inquiries) Marie-Louise Jersin, Senior Communications Partner
(US inquiries) Dora Gonzalez, Public Relations Specialist
[email protected]